CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
2023 · Nature Medicine · 152 citations
https://doi.org/10.1038/s41591-023-02404-6
K
Karthik Nath
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
78
Papers
950
Citations
11
h-index
13
i10-index
Karthik Nath is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: CAR-T cell therapy research & Lymphoma Diagnosis and Treatment & Multiple Myeloma Research and Treatments. The author has an h-index of 11, co-authored 67 publications.
ORCID: 0000-0002-3881-5681Papers by this author
worksPrognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma
2024 · Blood Cancer Journal · 26 citations
https://doi.org/10.1038/s41408-024-01048-0
Vitamin D Insufficiency and Clinical Outcomes with Chimeric Antigen Receptor T-Cell Therapy in Large B-cell Lymphoma
2022 · Transplantation and Cellular Therapy · 8 citations
https://doi.org/10.1016/j.jtct.2022.08.001
Decoding lysophosphatidic acid signaling in physiology and disease: mapping the multimodal and multinodal signaling networks
2025 · Signal Transduction and Targeted Therapy · 7 citations
https://doi.org/10.1038/s41392-025-02423-4
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
2024 · Haematologica · 4 citations
https://doi.org/10.3324/haematol.2024.286021
Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in a randomised trial of systemic therapy in early-stage follicular lymphoma
2024 · EBioMedicine · 1 citations
https://doi.org/10.1016/j.ebiom.2024.105468
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat